Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

• Status: Completed
• Trial end date: 2020-09-03
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arthrosi Therapeutics
• Treatments: Allopurinol; Febuxostat

Criteria

Key Inclusion Criteria:

• History of gout

• sUA > 7 mg/dL

• Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73m2

Key Exclusion Criteria:

• Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin

• History of cardiac abnormalities

• Active peptic ulcer disease or active liver disease

• History of kidney stones

• Allergy or intolerance to colchicine, febuxostat, and allopurinol